BeOne Medicines Achieves First GAAP Net Income and Positive Free Cash Flow in 2025, Driven by 40% Revenue Growth and Strong Product Performance

summarizeSummary

This annual report signals a significant financial inflection point for BeOne Medicines, marking its first year of GAAP net income and positive free cash flow. The substantial revenue growth, particularly from BRUKINSA becoming a global market leader, demonstrates strong commercial execution. Key pipeline advancements, including the first approval for sonrotoclax and positive Phase 3 data for the TEVIMBRA/ZIIHERA combination, further de-risk the company's future. The new debt facility and royalty sale proceeds significantly bolster liquidity, providing a solid financial foundation for continued R&D and commercial expansion. While legal challenges are noted, they are common in the industry and do not overshadow the company's robust operational and financial achievements.

check_boxKey Events

• Achieves First GAAP Net Income and Positive Free Cash Flow

  BeOne Medicines reported a net income of $286.9 million for 2025, a significant turnaround from a $644.8 million loss in 2024. The company also generated $941.7 million in positive free cash flow, compared to a negative $633.3 million in the prior year.

• Strong Revenue Growth Exceeds $5 Billion

  Total global revenue increased by 40.2% to $5.3 billion in 2025, up from $3.8 billion in 2024. This growth was primarily driven by increased sales of BRUKINSA and TEVIMBRA.

• BRUKINSA Becomes Global Market Leader

  BRUKINSA sales surged by 48.6% to $3.9 billion in 2025, establishing it as the global market leader in the BTK inhibitor class across B-cell malignancies.

• Sonrotoclax Receives First Global Approval and FDA Priority Review

  Sonrotoclax, a next-generation BCL2 inhibitor, received its first global regulatory approval in China in December 2025 for R/R MCL and CLL/SLL. It also received FDA Priority Review in November 2025 for R/R MCL, with potential for accelerated approval in H1 2026.

auto_awesomeAnalysis

This annual report signals a significant financial inflection point for BeOne Medicines, marking its first year of GAAP net income and positive free cash flow. The substantial revenue growth, particularly from BRUKINSA becoming a global market leader, demonstrates strong commercial execution. Key pipeline advancements, including the first approval for sonrotoclax and positive Phase 3 data for the TEVIMBRA/ZIIHERA combination, further de-risk the company's future. The new debt facility and royalty sale proceeds significantly bolster liquidity, providing a solid financial foundation for continued R&D and commercial expansion. While legal challenges are noted, they are common in the industry and do not overshadow the company's robust operational and financial achievements.